Top ▲
Target has curated data in GtoImmuPdb
Target id: 1876
Nomenclature: CD27
Systematic Nomenclature: TNFRSF7
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 260 | 12p13.31 | CD27 | CD27 molecule | |
Mouse | 1 | 250 | 6 59.32 cM | Cd27 | CD27 antigen | |
Rat | - | - | Cd27 | CD27 molecule |
Previous and Unofficial Names |
CD antigen 27 | CD27 molecule | Tp55 |
Database Links | |
Alphafold | P26842 (Hs), P41272 (Mm) |
ChEMBL Target | CHEMBL3713333 (Hs) |
Ensembl Gene | ENSG00000139193 (Hs), ENSMUSG00000030336 (Mm), ENSRNOG00000027466 (Rn) |
Entrez Gene | 939 (Hs), 21940 (Mm), 500318 (Rn) |
Human Protein Atlas | ENSG00000139193 (Hs) |
KEGG Gene | hsa:939 (Hs), mmu:21940 (Mm), rno:500318 (Rn) |
OMIM | 186711 (Hs) |
Pharos | P26842 (Hs) |
UniProtKB | P26842 (Hs), P41272 (Mm) |
Wikipedia | CD27 (Hs) |
Natural/Endogenous Ligands |
CD70 {Sp: Human} |
Adaptor proteins (Human) |
TRAF2, SIVA |
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
CD27 (TNFRSF7) is a co-stimulatory immune checkpoint molecule that is expressed on various immune cells, including T cells and NK (natural killer) cells. The endogenous ligand for CD27 is CD70. CD27 interacts with various TRAF adaptor proteins and apoptosis regulatory protein SIVA (SIVA1). It has been recognized as playing an important role in priming, enhancing and sustaining a productive anti-cancer (CD8 T cell) adaptive immune response. CD27 is an immuno-oncology target [1-2]. The agonistic CD27 antibody varlilumab (CDX-1127) is being evaluated for efficacy against solid cancers and lymphomas in early phase clinical trials. Click here to link to ClinicalTrials.gov's list of registered varlilumab trials. |
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
1. Buchan SL, Rogel A, Al-Shamkhani A. (2018) The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood, 131 (1): 39-48. [PMID:29118006]
2. van de Ven K, Borst J. (2015) Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy, 7 (6): 655-67. [PMID:26098609]